← All organizations
Highest phase reached
Phase 4
First clinical trial
Apr 1, 1987First marketed drug
Oct 23, 1946First NDA
Oct 23, 1946Last known activity
Apr 14, 2025
Acquired by Novartis on Jan 1, 1996
Timeline
1880s
- Jan 1, 1886
Sandoz— Founded
1950s
- Jan 1, 1950
Basler IG— Acquired
- Jun 1, 1956
deslanoside— NDA Organization
1970s
- Jan 1, 1975
Rogers Seed Co— Acquired
- Jan 1, 1976
Northrup King— Acquired
1990s
- Jan 1, 1994
Gerber— Acquired
- Jan 1, 1995
Genetic Therapy, Inc.— Acquired
- Apr 28, 1995
timolol— NDA Secondary Org
- Jan 1, 1996
Novartis— Acquired By
2000s
- Apr 6, 2007
cefdinir— Marketing Organization
- May 1, 2009
EBEWE Pharma— Acquired
2010s
- Apr 19, 2010
Oriel Therapeutics— Acquired
- Oct 1, 2011
Falcon Pharmaceuticals— Acquired
- Jul 1, 2012
Savage Labs— Acquired
Drugs by trial phase (93 distinct, 138 trials)
Phase 4 (8 own, 2 via acquisition)
Phase 3 (26 own, 5 via acquisition)
Phase 2 (0 own, 3 via acquisition)
Phase 1 (47 own, 0 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Approved for
- Acromegaly
- Apnea
- Arrhythmias, Cardiac
- Arthritis, Rheumatoid
- Atherosclerosis
- Carcinoid Tumor
- Diabetes Insipidus
- Dyslipidemias
- Epilepsy
- Gout
- Heart Failure
- Hemorrhage
- Hypercholesterolemia
- Hypertension
- Migraine Disorders
- Muscle Relaxation
- Muscular Dystrophy, Duchenne
- Nasal Obstruction
- Neoplasms
- Obesity
- Pain
- Spondylitis, Ankylosing
- Tension-Type Headache
- Tuberculosis
- Tuberculosis, Pulmonary
- Uterine Hemorrhage
- Vipoma
Studied for
- Acquired Immunodeficiency Syndrome
- Anemia
- Anemia, Iron-Deficiency
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Bipolar Disorder
- Breast Neoplasms
- Cataract
- Chest Pain
- Communicable Diseases
- Cytomegalovirus Infections
- Cytomegalovirus Retinitis
- Deficiency Diseases
- Depression
- Diabetes Mellitus, Type 2
- Diarrhea
- Disruptive, Impulse Control, and Conduct Disorders
- Dysentery
- Epilepsy
- Headache
- Hepatitis C
- Hepatitis C, Chronic
- Hirsutism
- HIV Infections
- Hypertension
- Immunologic Deficiency Syndromes
- Infections
- Inflammation
- Kidney Diseases
- Leukopenia
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Malnutrition
- Migraine Disorders
- Neutropenia
- Osteoarthritis
- Osteoporosis
- Parkinson Disease
- Pharyngeal Diseases
- Pharyngitis
- Proctitis
- Psoriasis
- Psychotic Disorders
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Retinitis
- Rheumatic Diseases
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Seizures
- Signs and Symptoms
- Sinusitis
- Thrombocytopenia
- Viremia
- Virus Diseases
- Vomiting
Marketed drugs (373)
Subsidiaries (11 direct, 12 total across the full acquisition tree)
Recent trials (50)
- NCT06847724Lead sponsorPhase 3Apr 14, 2025
- NCT06587451Lead sponsorPhase 3Jan 1, 2025
- NCT06159790Lead sponsorPhase 3Feb 28, 2024
- NCT06153238Lead sponsorPhase 1Feb 28, 2024
- NCT05887843Lead sponsorPhase 1Jun 8, 2023
- NCT05590598Study directorPhase 3Jan 24, 2023
- NCT05590598Lead sponsorPhase 3Jan 24, 2023
- NCT05588804Study directorPhase 3Oct 20, 2022
- NCT05588804Lead sponsorPhase 3Oct 20, 2022
- NCT05282004Lead sponsorPhase 3May 16, 2022
- NCT05258747Study directorPhase 1Apr 7, 2022
- NCT05258747Lead sponsorPhase 1Apr 7, 2022
- NCT05311475Lead sponsorPhase 3Apr 4, 2022
- NCT05311475Study directorPhase 3Apr 4, 2022
- NCT05161806Lead sponsorPhase 3Jan 25, 2022
Details
- Founded
- Basel, CH Jan 1, 1886
- First NDA
- Oct 23, 1946
- Last known activity
- Apr 14, 2025
Designations held
- Priority review